| Original language | English (US) |
|---|---|
| Pages (from-to) | E11-E14 |
| Journal | American journal of hematology |
| Volume | 98 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2023 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. / Paul, Shilpa; Kantarjian, Hagop; Sasaki, Koji et al.
In: American journal of hematology, Vol. 98, No. 1, 01.2023, p. E11-E14.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia
AU - Paul, Shilpa
AU - Kantarjian, Hagop
AU - Sasaki, Koji
AU - Marx, Kayleigh
AU - Jain, Nitin
AU - Savoy, J. Michael
AU - DiPippo, Adam
AU - Jammal, Nadya
AU - Bravo, Guillermo Montalban
AU - Kadia, Tapan
AU - Garcia-Manero, Guillermo
AU - Short, Nicholas J.
AU - Ravandi, Farhad
AU - Jabbour, Elias
N1 - Funding Information: : Advisory board or honoraria from Novartis, Pfizer, Amgen. : Research funding or honoraria from Pfizer, Amgen, Bristol Myers Squibb, Novartis, ARIAD, Astex Pharmaceuticals, AbbVie, Agios, Cyclacel, Immunogen, Jazz Pharmaceuticals. : Research funding from Novartis. Honoraria from Otsuka. Advisory board for Takeda, Pfizer, Novartis. : No conflict of interest. : Research funding from IFM Therapeutics. : Research Funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, Servier, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Incyte, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics, Kite/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, TransThera Sciences, Novartis. Advisory Board or honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, Beigene, Cellectis, TG Therapeutics, MEI Pharma, Ipsen, CareDX. : Grant or research support from AbbVie Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Cellenkos, Cyclacel, Delta‐Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron. Consulting for AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi‐Aventis, Servier. Honoraria from Genzyme. : Research Grants from Takeda Oncology, Astellas Pharma Inc., Stemline Therapeutics, Inc, and Xencor. Honoraria from Amgen, Jazz Pharmaceuticals, Novartis and Pfizer. : Research funding from Bristol Myers Squibb, Amgen, Macrogenics, Xencor, Selvita, Cellerant. Honoraria from Amgen, Pfizer, Astellas Pharma, Orsenix, Celgene, Agios, AbbVie/Genentech, AstraZeneca, Bristol Myers Squibb, Takeda, Jazz Pharmaceuticals, Novartis. Consulting or advisory role for Amgen, Astellas Pharma, Orsenix, Celgene, Jazz Pharmaceuticals, Agios, AbbVie/Genentech, Bristol Myers Squibb, AstraZeneca, Taiho Oncology, Syros Pharmaceuticals, Certara Inc. : Research funding and consultancy from Abbvie, Amgen, Adaptive Biotechnologies, BMS, Genentech, Novartis, Pfizer, Takeda. Shilpa Paul Hagop Kantarjian Koji Sasaki Kayleigh Marx, Adam DiPippo, J. Michael Savoy, Nadya Jammal Guillermo Montalban‐Bravo Nitin Jain Tapan Kadia Nicholas J. Short Farhad Ravandi Eillas Jabbour
PY - 2023/1
Y1 - 2023/1
UR - http://www.scopus.com/inward/record.url?scp=85131522186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131522186&partnerID=8YFLogxK
U2 - 10.1002/ajh.26622
DO - 10.1002/ajh.26622
M3 - Letter
C2 - 35633516
AN - SCOPUS:85131522186
SN - 0361-8609
VL - 98
SP - E11-E14
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 1
ER -